VVUS Share Price

Open 1.40 Change Price %
High 1.43 1 Day -0.02 -1.43
Low 1.36 1 Week -0.02 -1.43
Close 1.38 1 Month 0.29 26.61
Volume 337750 1 Year 0.32 30.19
52 Week High 1.85
52 Week Low 0.92
VVUS Important Levels
Resistance 2 1.44
Resistance 1 1.42
Pivot 1.39
Support 1 1.34
Support 2 1.32
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

VIVUS, Inc. (NASDAQ: VVUS)

VVUS Technical Analysis 4
As on 9th Dec 2016 VVUS Share Price closed @ 1.38 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.18 & Strong Buy for SHORT-TERM with Stoploss of 1.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
VVUS Target for December
1st Target up-side 1.58
2nd Target up-side 1.75
3rd Target up-side 1.92
1st Target down-side 1.1
2nd Target down-side 0.93
3rd Target down-side 0.76
VVUS Other Details
Segment EQ
Market Capital 1186283776.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vivus.com
VVUS Address
VVUS
351 East Evelyn Avenue
Mountain View, CA 94041
United States
Phone: 650-934-5200
Interactive Technical Analysis Chart VIVUS, Inc. ( VVUS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on VIVUS, Inc.
VVUS Business Profile
VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate. It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes. Its drug also includes STENDRA, or avanafil.